View:
Download DOC
Download PDF
Download XLS
Form 8-A12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

CRISPR THERAPEUTICS AG

(Exact name of registrant as specified in its charter)

 

 

 

Switzerland   Not Applicable
(State of incorporation or organization)   (I.R.S. Employer Identification No.)

CRISPR Therapeutics AG

Aeschenvorstadt 36

4051 Basel

Switzerland

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

CT Corporation System

111 Eighth Avenue

New York, NY 10011

(212) 894-8800

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

  

Name of exchange on which

each class is to be registered

Common Shares, CHF 0.03 nominal value per share   The NASDAQ Stock Market LLC

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.   ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.   ☐

Securities Act registration statement file number to which the form relates: 333-213577

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 

 

Item 1. Description of Registrant’s Securities to be Registered.

A description of the common shares, CHF 0.03 nominal value per share, of CRISPR Therapeutics AG, a Swiss stock corporation (the “Registrant”), to be registered hereunder is contained in the section entitled “Description of Share Capital and Articles of Association” in the prospectus included in the Registrant’s Registration Statement on Form S-1 (File No. 333-213577), initially filed with the Securities and Exchange Commission (the “Commission”) on September 9, 2016, as amended from time to time (the “Registration Statement”), and is incorporated herein by reference. Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.

 

Item 2. Exhibits.

Under the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed with this registration statement because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities to be registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

    CRISPR THERAPEUTICS AG
Date: October 18, 2016     By:   /s/ Marc A. Becker
      Marc A. Becker
      Chief Financial Officer